165 related articles for article (PubMed ID: 35330827)
41. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
Tokudome N; Koh Y; Akamatsu H; Fujimoto D; Okamoto I; Nakagawa K; Hida T; Imamura F; Morita S; Yamamoto N
BMC Cancer; 2020 Feb; 20(1):103. PubMed ID: 32028909
[TBL] [Abstract][Full Text] [Related]
42. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV
Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424
[TBL] [Abstract][Full Text] [Related]
44. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
[TBL] [Abstract][Full Text] [Related]
45. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
[TBL] [Abstract][Full Text] [Related]
46. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
[TBL] [Abstract][Full Text] [Related]
47. Afatinib for the treatment of metastatic non-small cell lung cancer.
Joshi M; Rizvi SM; Belani CP
Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
[TBL] [Abstract][Full Text] [Related]
48. Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis.
Liu J; Sun X; Du Q; Yao J; Dai M; Cheng Q; Xu H; Li Y; Liu X; Zhang M; Zhou Y; Yang Y
Breast Cancer (Dove Med Press); 2022; 14():491-504. PubMed ID: 36575687
[TBL] [Abstract][Full Text] [Related]
49. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
[TBL] [Abstract][Full Text] [Related]
50. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
51. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
[TBL] [Abstract][Full Text] [Related]
52. Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare
Zöchbauer-Müller S; Kaserer B; Prosch H; Cseh A; Solca F; Bauer MJ; Müllauer L
Front Oncol; 2020; 10():593852. PubMed ID: 33575211
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
Chen Q; Ouyang D; Anwar M; Xie N; Wang S; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W; Ouyang Q
Front Oncol; 2020; 10():811. PubMed ID: 32528890
[No Abstract] [Full Text] [Related]
56. Discovery of Potent and Selective Covalent Inhibitors of HER2
Hicken EJ; Brown K; Dwulet NC; Gaudino JJ; Hansen EP; Hartley DP; Kowalski JP; Laird ER; Lazzara NC; Li B; Mou TC; Mutryn MF; Oko L; Pajk S; Pipal RW; Rosen RZ; Shelp R; Singh A; Wang J; Wise CE; Wong C; Wong JY
J Med Chem; 2024 Jun; 67(11):9759-9771. PubMed ID: 38820338
[TBL] [Abstract][Full Text] [Related]
57. Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study.
Zhang L; Wu X; Zhou J; Zhu M; Yu H; Zhang Y; Zhao Y; Han Z; Guo Y; Guan X; Wang X; Xu H; Sun L; Zhang J; Zhuang M; Xie L; Yu S; Chen P; Feng J
Front Oncol; 2021; 11():699323. PubMed ID: 34336688
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis.
Rubiera-Pebe R; Hicks JK; Tanvetyanon T
Cancer Treat Res Commun; 2021; 28():100407. PubMed ID: 34090219
[TBL] [Abstract][Full Text] [Related]
59. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
[TBL] [Abstract][Full Text] [Related]
60. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
Huang CH; Ju JS; Chiu TH; Huang AC; Tung PH; Wang CC; Liu CY; Chung FT; Fang YF; Guo YK; Kuo CS; Yang CT
Int J Cancer; 2022 Feb; 150(4):626-635. PubMed ID: 34558665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]